Outcome at 26 weeks
| COBRA (n=81) | COBRA-light (n=81) | Unadjusted β (95% CI) | p Value | Adjusted* β (95% CI) | p Value | |
|---|---|---|---|---|---|---|
| Δ DAS44 | –2.50 (±1.21) | –2.18 (±1.1) | 0.33 (–0.03 to 0.68) | 0.08 | 0.21 (–0.11to 0.53) | 0.19 |
| AUC DAS44 | 62.1 (±17.6) | 64.0 (±25.4) | 2.2 (–4.5 to 9.0) | 0.52 | ||
| Δ DAS44 CRP | −2.15 (±1.09) | −2.10 (±1.09) | 0.04 (−2.9 to 0.38) | 0.79 | −0.06 (−0.36 to 0.23) | 0.68 |
| Δ HAQ | –0.8 (±0.6) | –0.8 (±0.7) | 0.1 (–0.2 to 0.3) | 0.61 | 0.1 (–0.1 to 0.2) | 0.49 |
| Δ Tender joints | –14.0 (±10.9) | –12.8 (±11.1) | 1.2 (–2.3 to 4.7) | 0.49 | 0.3 (–2.0 to 2.5) | 0.81 |
| Δ Swollen joints | –11.3 (±6.1) | –9.6 (±6.2) | 1.6 (–0.3 to 3.5) | 0.10 | 0.2 (–0.9 to 1.4) | 0.67 |
| Δ ESR, mm/h† | –21.5 (–37; −8) | –13.5 (–34; −4) | 1.5 (1.2 to 2.1) | 0.003 | 1.5 (1.2 to 2.0) | 0.002 |
| Δ CRP, mg/l† | –9.5 (–25; −1) | –8.5 (–29;-1) | 1.1 (0.7 to 1.6) | 0.67 | 1.0 (0.8 to 1.4) | 0.42 |
| Δ Patient VAS disease activity | –31 (±31) | –41 (±32) | –9.3 (–19.3 to 0.7) | 0.07 | –5.6 (–13.8 to 2.6) | 0.18 |
| Δ Patient VAS pain | –32 (±30) | –34 (±30) | –0.5 (–10.1 to 9.2) | 0.55 | –2.9 (–10.5 to 4.7) | 0.25 |
| Δ Patient VAS global health | –33 (±32) | –33 (±30) | –2.9 (–12.5 to 6.7) | 0.92 | –4.7 (–12.6 to 3.3) | 0.45 |
| Δ Physician VAS disease activity | –31 (±20) | –31 (±25) | –0.6 (–7.9 to 6.6) | 0.98 | –3.1 (–9.4 to 3.1) | 0.43 |
Data are expressed as mean (±SD) or median (IQR) change from baseline. Δ=change from baseline value. Significance between groups was tested with linear regression.
*Adjusted for baseline value.
†Regression based on LNESR and LNCRP.
anti-CCP, anti-cyclic citrullinated peptide; AUC, area under the curve; CRP, C-reactive protein; DAS44, 44-joint disease activity score; ESR, erythrocytesedimentation rate; HAQ, health assessment questionnaire; RF, rheumatoid factor; VAS, visual analogue scale.